Developing a new generation of anti-inflammatory drugs
Investment/ Collaboration Opportunity Highlights:
-
Investment round: Morria is currently in the process of completing a financing round coupled with a listing on a public exchange in the US. The company has already received clearance from the SEC (F20) and FINRA (F1) and expect final approval by mid Feb 2013.
-
Investment to-date: $14m
About the company
-
Morria Biopharmaceuticals Plc is a drug development company focused on the development of novel, non-steroidal, anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) which represent a novel class of drugs
-
Morria aims to capitalize on its proprietary drug platform by advancing unique drug candidates from pre-clinical stages to clinical proof-of-concept, thus generating safety and efficacy data while de-risking its drug development program by identifying appropriate licensing partners for each program
-
Morria is currently in the process of listing on the stock exchange in the US.
Our products
-
Morria’s lead products are first-in-class, novel, non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID) focus on one of the most sought after pharmaceutical targets in inflammation research: the sPLA2 family.
-
The Company has two lead products that have the potential to replace steroids in clinical development, MRX-4 targeting hay fever / allergic rhinitis ($22 billion market including asthma) and MRX-6 targeting eczema ($3 billion market) that have completed Phase IIa studies, in addition to three other products in preclinical stages that target: ophthalmology (dry eye and conjunctivitis), inflammatory bowel disease and cystic fibrosis.
Development Milestones
-
Two studies are scheduled for completion by the end of 2013, Phase IIb study on a topical cream for contact dermatitis (MRX6) and a Phase IIb study on a nasal spray for allergic rhinitis (MRX4) to be carried out at the Vienna Challenge Chamber.
-
Additional pre-clinical modules are also scheduled for 2013.
Contact details
Yuval Cohen – President
yuval@morria.com
1586128900.png)